Global action plan for influenza vaccines

Global Action Plan for Influenza Vaccines (GAP)

Global Action Plan for Influenza Vaccines (GAP) was a comprehensive strategy to reduce the present global shortage of influenza vaccines for seasonal epidemics and pandemic influenza in all countries of the world through three major approaches:
- Increase in seasonal vaccine use
- Increase in vaccine production capacity
- Research and development

GAP was launched in 2006 and closed in 2016.

Objective 1: increase in seasonal vaccine use

The first GAP approach is to encourage countries to increase their seasonal vaccine use.
Increased use of seasonal influenza vaccine will reduce disease burden of seasonal influenza infections, contribute towards the preparedness of countries to respond to an eventual pandemic and motivate industry to develop greater capacity for manufacturing vaccines.

Objective 2: increase in vaccine production capacity

The second GAP approach concentrates on increasing production capacity for pandemic vaccines without expectation for a commensurate increase in the demand for seasonal vaccine.
Short term – produce enough vaccine to immunize two billion people; this vaccine should be available on the market six months after transfer of the vaccine prototype strain to industry.
Medium and long term – produce enough vaccine to immunize 70% of the world’s population with two doses.

Objective 3: research and development

The third GAP approach encourages to use new technologies to develop more potent and effective influenza vaccines that are:
(a) capable of inducing protective responses after one dose, and/or
(b) induce broad-spectrum and long-lasting immunity against both seasonal and pandemic influenza strains.

About GAP:

What's new:

  • 5 April 2017

    Following the GAP final consultation on 15-16 November 2016, the GAP Advisory Group has sent to the WHO Director-General a short report with recommendations to ensure that the results achieved by the GAP programme are maintained and the remaining work is carried forward in a coordinated manner by the influenza stakeholders.

  • 16 December 2015

    Third WHO Consultation on Global Action Plan for Influenza Vaccines (GAP III)

    The third and final GAP consultation took place in Geneva, Switzerland on 15-16 November 2016. Please click on the link below for more information about the meeting.

  • 21 August 2015

    The report of the 10th GAP Advisory Group meeting held 19 March 2015 in Sao Paulo, Brazil is now available.

  • 11 June 2015

    GAP presented at Second APACI Summit

    An update on GAP was provided during the 2nd Asia-Pacific Influenza Summit in Hanoi, Viet Nam. Since 2006, GAP has supported Viet Nam in establishing pandemic and seasonal influenza vaccine production and regulatory capacity.


OBJECTIVE 1________________

OBJECTIVE 2_________________

OBJECTIVE 3________________


Contact us:

World Health Organization
Global Action Plan for Influenza Vaccines (GAP)
20, avenue Appia
1211 Geneva 27, Switzerland

Key WHO Information

Director-General and senior management

Governance of WHO
WHO Constitution, Executive Board and World Health Assembly

Media centre
News, events, fact sheets, multimedia and contacts

International travel and health
Publication on travel risks, precautions and vaccination requirements

World Health Report
Annual report on global public health and key statistics